Quick Answer
Bolt Biotherapeutics, Inc. reported Operating Income of -$36.11 million for fiscal year 2025.
Bolt Biotherapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$36.11M | +50.6% |
| 2024 | -$73.05M | +4.1% |
| 2023 | -$76.20M | +15.6% |
| 2022 | -$90.32M | +2.7% |
| 2021 | -$92.79M | -88.7% |
| 2020 | -$49.18M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$7.70M | +53.2% | +16.4% |
| June 30, 2025 | -$9.21M | +59.2% | +24.0% |
| March 31, 2025 | -$12.12M | +29.1% | +26.3% |
| September 30, 2024 | -$16.44M | +9.6% | +27.2% |
| June 30, 2024 | -$22.60M | -13.9% | -32.2% |
| March 31, 2024 | -$17.09M | +7.2% | +6.0% |
| September 30, 2023 | -$18.18M | +18.6% | +8.3% |
| June 30, 2023 | -$19.83M | +14.0% | -7.7% |
- Bolt Biotherapeutics, Inc. showed an increase of +50.6% in Operating Income compared to the prior fiscal year.
- Over the 2020–2025 period, Bolt Biotherapeutics, Inc.’s operating income has grown by 26.6% (from -$49.18 million to -$36.11 million).
- The most recent figure is from Bolt Biotherapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: